Skip To Main Content
Xavier Barril on Muck Rack

Xavier Barril

As seen in: Nature, PLOS ONE, Royal Society of Chemistry, BioRxiv, Drug Discovery & Development
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xavier

Contact Xavier, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Quasi-Bound State as a Predictor of Relative Binding Free Energy

|
By Álvaro Serrano-Morrás, Yvonne Westermaier, Maciej Majewski, Xavier Barril
| dx.doi.org
Open in Who Shared Issue with article?

Syntheses of Differentially Fluorinated Triazole-Based 1-Deoxysphingosine Analogues en route to SphK Inhibitors

|
By Xavier Barril, Sergio Castillón, Maria Isabel Matheu, Varbina Ivanova
| Royal Society of Chemistry Verified
Syntheses of Differentially Fluorinated Triazole-Based 1-Deoxysphingosine Analogues en route to SphK Inhibitors This study focuses on the stereoselective syntheses of 1-deoxysphingosine analogues as potential inhibitors of sphingosine kinase (SphK), particularly targeting its isoforms SphK1 and SphK2, which are implicated in cancer progression and therapy resistance.
Open in Who Shared Issue with article?

Syntheses of differentially fluorinated triazole-based 1-deoxysphingosine analogues en route to SphK inhibitors

|
By Varbina Ivanova, Universitat de Barcelona, Xavier Barril, M. Isabel Matheu
| Royal Society of Chemistry Verified
Syntheses of differentially fluorinated triazole-based 1-deoxysphingosine analogues en route to SphK inhibitors† This study focuses on the stereoselective syntheses of 1-deoxysphingosine analogues as potential inhibitors of sphingosine kinase (SphK), particularly targeting its isoforms SphK1 and SphK2, which are implicated in cancer progression and therapy resistance.
Open in Who Shared Issue with article?
See all 8 articles